Pancreatic cancer statistics
The statistics highlight the problem of pancreatic cancer. We believe they are unacceptable, which is why we have made it our mission to drastically improve survival rates and quality of life for people impacted by pancreatic cancer. Read more about our approach to tackling pancreatic cancer.
- In 2019, it is estimated 3,599 new cases of pancreatic cancer were diagnosed (1).
- In 2019, it is estimated 3051 Australians died from pancreatic cancer (1).
- The Australian five-year survival rate for pancreatic cancer is 10.7% (1).
- Pancreatic cancer is the 11th most funded cancer for research by the Australian government through the National Health and Medical Research Council (2), despite being the 5th most common cancer killer in Australia (1).
- It is predicted pancreatic cancer will become the 3rd biggest cancer killer in Australia in 2020.
- Median life expectancy after diagnosis of pancreatic cancer is less than 12 months for 80 per cent of people diagnosed (4)(5)(6).
- Australian Institute of Health and Welfare 2019. Cancer in Australia 2019. Cancer series no.119. no. CAN 123. Canberra: AIHW.
- Parliament of Australia, 28 November 2017. ‘Select Committee into Funding for Research into Cancers with Low Survival Rates – Report’.
- Rahib, L., Smith, B., Aizenberg, R., Rosenzweig, A., Fleshman, J. & Matrisian, L. (2014). Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 74(11), 2913-21.
- Ducreux, A. Sa. Cuhna, C. Caramella, A. Hollebecque, P. Burtin, D. Goéré,
T. Seufferlein, K. Haustermans, J. L. Van Laethem, T. Conroy & D. Arnold. (2015). Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26 (Supplement 5): v56–v68, 2015. doi:10.1093/annonc/mdv295
- C. Gandy, A. P. Barbour, J. Samra, M. Nikfariam, K. Haghighi, J. G. Kench, P. Saxena, D. Goldstein. (2016). Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. The Medical Journal of Australia: v204(11). https://doi.org/10.5694/mja16.00061
- M. A. Tempero, M.P. Malafa, M. Al-Hawary, H. Asbun, A. Bain, S. W. Behrman, A. B. Benson III, E. Binder, D. B. Cardin, C. Cha, E. G. Chiorean, V. Chung, B. Czito, M. Dillhoff, E. Dotan, C. R. Ferrone, J. Hardacre, W. G. Hawkins,J. Herman, A. H. Ko, S. Komanduri, A. Koong, N. LoConte, A. M. Lowy, C. Moravek, E. K. Nakakura, E. M. O’Reilly, J. Obando, S. Reddy, C. Scaife, S. Thayer, C. D. Weekes, R. A. Wolff, B. M. Wolpin, J. Burns; and S. Darlow. (2017). Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15(8):1028–1061 doi: 10.6004/jnccn.2017.0131